Prostate cancer
On this page:
The Ottawa Hospital is conducting cutting-edge research to improve our understanding of prostate cancer and develop better approaches for treatment and prevention. This page includes selected news stories about our prostate cancer research, links to researchers working in this area and related resources. Learn more below.
Research News
Labs and Groups
These research teams may include multiple scientists, investigators, staff and trainees all working towards a common goal, or they can represent a single scientist and their team.
Addison Cancer Research Lab
Ardolino Cancer Immunology Lab
Urologic Oncology Group
Clinical Trials
The following list of clinical trials at The Ottawa Hospital is pulled from ClinicalTrials.gov, which is hosted by the U.S. National Library of Medicine and only available in English. If you find a clinical trial that interests you, you can bring the information to the next appointment with your care team and ask if you are eligible for the study. If so, they may be able to refer you to the study team. If you email the study team directly, we can guarantee a response. Learn more about participating in research and clinical trials.
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy (NCT05169112)
Prostate Cancer View DetailsPlatinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes (NCT06439225)
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer View DetailsEvaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers (NCT07252726)
Metastatic Breast Cancer, Metastatic Prostate Cancer View DetailsDose Escalation For INtraprostatic LEsions (NCT05851547)
Prostatic Neoplasms View DetailsInternational Registry for Men With Advanced Prostate Cancer (IRONMAN) (NCT03151629)
Prostate Cancer View DetailsA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT07225946)
Prostatic Neoplasms, Castration-Resistant View DetailsGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (NCT04812366)
Prostate Cancer View DetailsStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (NCT06136624)
Prostate Cancer Metastatic View DetailsStudy of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) (NCT06654336)
Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer View DetailsDocetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (NCT06592924)
Prostate Cancer (Adenocarcinoma) View DetailsA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (NCT06136650)
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms View DetailsTesting Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer (NCT05946213)
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8 View DetailsPublications
The following research publications from The Ottawa Hospital are pulled from PubMed, with publication date of 2020 or later. Note that PubMed is hosted by the U.S. National Library of Medicine and is only available in English.
Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
2026-10-03 Go to publicationPSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.
2026-10-03 Go to publicationNatural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR).
2026-10-01 Go to publicationExternal validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.
2026-10-01 Go to publicationDifferential Association of Posttestosterone Recovery PSA Kinetics With Progression and Metastatic Outcomes in Nonmetastatic Prostate Cancers.
2026-09-28 Go to publication